Phaseline

Targets › CD5

CD5 (T-cell surface glycoprotein CD5): drug programs, companies and trials

12 programs from 9 companies in 19 trials: 18 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2026.

Lymphoid-specific receptor expressed by all T-cells and in a subset of B-cells known as B1a cells. Plays a role in the regulation of TCR and BCR signaling, thymocyte selection, T-cell effector differentiation and immune tolerance. (UniProt, P06127)

Open in Phaseline: the race on CD5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
March BiosciencesMB-105
CD5-targeted CAR T-cell therapy
CD5Phase 2Lymphoma, T-CellFeb 2028
Essen BiotechCD5/CD7 CAR-T
Chimeric antigen receptor T cells targeting CD5 and CD7
CD5, CD7Phase 1T Cell LymphomaDec 2026
Beijing GoBroad HospitalAutologous CD5 CAR T-cells
anti-CD5 CAR-T cell therapy
CD5Phase 1T-Cell Acute Lymphocytic LeukemiaDec 2026
Beijing GoBroad HospitalNewly matched donor-derived CD5 CAR T-cells
anti-CD5 CAR-T cell therapy
CD5Phase 1T-Cell Acute Lymphocytic LeukemiaDec 2026
Peking University People's HospitalCD5-targeted CAR-T cells
Nanobody-based anti-CD5 CAR-T cell therapy
CD5Phase 1Precursor T-Cell Lymphoblastic Leukemia-LymphomaDec 2026
Chongqing Precision BiotechAnti-CD5 CAR NK cells
anti-CD5 CAR-NK cell therapy
CD5Phase 1T-ALL/LymphomaMar 2027
Beijing GoBroad Hospitalumbilical cord blood CD19-BCMA CAR-T cells
dual-targeted CAR-T cell therapy targeting CD19 and BCMA
CD19, BCMA, CD5, CD7Phase 1Refractory Lupus Nephritis; T-Cell Non-Hodgkin LymphomaApr 2027
Beijing BiotechEB-CAR5-NK
CD5-targeted allogeneic CAR-NK cells
CD5Phase 1B2 ThymomaJun 2027
Baylor College of MedicineAllogeneic CD5.CAR/28zeta CAR T cells
CD5-directed CAR T cell therapy with 28zeta costimulatory domain
CD5Phase 1T-cell Acute Lymphoblastic LymphomaJun 2028
Baylor College of MedicineAutologous CD5.CAR/28zeta CAR T cells
CD5-directed CAR T cell therapy with 28zeta costimulatory domain
CD5Phase 1T-cell Acute Lymphoblastic LymphomaJun 2028
Vittoria BiotherapeuticsSenza5 CART5
CD5-deleted CAR-T cell therapy targeting CD5-positive T cell lymphomas
CD5Phase 1T Cell Non-Hodgkin LymphomaAug 2028
M.D. Anderson Cancer CenterCAR.5/IL15-transduced CB-NK cells
CD5-targeted CAR NK cells engineered with IL-15
CD5, IL15Phase 1Hematological MalignancyDec 2030

Conditions

T-Cell Acute Lymphocytic Leukemia (6) T-cell Acute Lymphoblastic Lymphoma (2) Refractory Lupus Nephritis (2) T-Cell Non-Hodgkin Lymphoma (2) Hematological Malignancy (1) T Cell Lymphoma (1) T Cell Non-Hodgkin Lymphoma (1) Lymphoma, T-Cell (1) T-ALL/Lymphoma (1) Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) B2 Thymoma (1)

Modalities

other (8), mixed (2), small molecule (1), protein or peptide (1)

Companies

Beijing GoBroad Hospital (3) Baylor College of Medicine (2) M.D. Anderson Cancer Center (1) Essen Biotech (1) Vittoria Biotherapeutics (1) March Biosciences (1) Chongqing Precision Biotech (1) Peking University People's Hospital (1) Beijing Biotech (1)

Related targets

CD7 (2) IL15 (1) CD19 (1) BCMA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.